uu.seUppsala universitets publikasjoner
Endre søk
RefereraExporteraLink to record
Permanent link

Direct link
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Annet format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annet språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf
Direct comparisons of effectiveness and safety of treatment with Apixaban, Dabigatran and Rivaroxaban in atrial fibrillation
Umea Univ, Dept Publ Hlth & Clin Med, Sundsvall, Sweden.
Umea Univ, Dept Publ Hlth & Clin Med, Sundsvall, Sweden.
Umea Univ, Dept Publ Hlth & Clin Med, Sundsvall, Sweden.
Uppsala universitet, Medicinska och farmaceutiska vetenskapsområdet, Medicinska och farmaceutiska vetenskapsområdet, centrumbildningar mm, Uppsala kliniska forskningscentrum (UCR).ORCID-id: 0000-0002-2141-6086
Vise andre og tillknytning
2020 (engelsk)Inngår i: Thrombosis Research, ISSN 0049-3848, E-ISSN 1879-2472, Vol. 185, s. 135-141Artikkel i tidsskrift (Fagfellevurdert) Published
Abstract [en]

Introduction: Direct oral anticoagulants (DOACs) have been proven non-inferior or superior to warfarin in preventing stroke and systemic embolism, with a lower risk of major hemorrhage, in patients with non-valvular atrial fibrillation (NVAF). We sought to investigate whether effectiveness and safety differs among apixaban, rivaroxaban and dabigatran.

Materials and methods: Patients with newly initiated DOAC treatment were identified from the Swedish anticoagulation quality registry, ranging from January 1, 2013 to December 31, 2015. Patients were assigned to apixaban, dabigatran or rivaroxaban cohorts based on initiated DOAC and dose (standard or reduced). Baseline characteristics and endpoints were retrieved from validated Swedish quality registers and the National Patient Registry. Cohorts were matched using full optimal matching and directly compared.

Results: A total of 25,843 NVAF patients were included. Patients treated with standard dose apixaban or dabigatran had lower risk of major bleeding than patients treated with rivaroxaban, HR 0.69 (95% CI 0.54-0.88) and HR 0.64 (95% CI 0.48-0.87). Regarding reduced dose, patients treated with apixaban had lower risk of major bleeding than those treated with dabigatran or rivaroxaban, HR 0.62 (95% CI 0.44-0.88) and HR 0.45 (95% CI 0.33-0.61). In reduced dose, patients treated with dabigatran had the lowest all-cause mortality. No differences in effectiveness were found.

Conclusions: In this large real-world NVAF cohort, direct comparisons show a favorable bleeding risk profile for dabigatran and apixaban in standard dose, and for apixaban in reduced dose. No differences in effectiveness were found. This study confirms previous indirect DOAC comparisons. Further studies are needed.

sted, utgiver, år, opplag, sider
PERGAMON-ELSEVIER SCIENCE LTD , 2020. Vol. 185, s. 135-141
Emneord [en]
Dabigatran, Rivaroxaban, Treatment outcome, Apixaban, Anticoagulants, Atrial fibrillation
HSV kategori
Identifikatorer
URN: urn:nbn:se:uu:diva-403245DOI: 10.1016/j.thromres.2019.11.010ISI: 000506413800023PubMedID: 31816553OAI: oai:DiVA.org:uu-403245DiVA, id: diva2:1389010
Forskningsfinansiär
Swedish Heart Lung Foundation, 20150435Tilgjengelig fra: 2020-01-28 Laget: 2020-01-28 Sist oppdatert: 2020-01-28bibliografisk kontrollert

Open Access i DiVA

Fulltekst mangler i DiVA

Andre lenker

Forlagets fulltekstPubMed

Personposter BETA

Renlund, Henrik

Søk i DiVA

Av forfatter/redaktør
Renlund, Henrik
Av organisasjonen
I samme tidsskrift
Thrombosis Research

Søk utenfor DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetric

doi
pubmed
urn-nbn
Totalt: 1 treff
RefereraExporteraLink to record
Permanent link

Direct link
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Annet format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annet språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf